DSM Nutritional Products, Kaiseraugst, Switzerland.
Atlantia Clinical Trials, Cork, Ireland.
J Nutr. 2023 Jan;153(1):96-105. doi: 10.1016/j.tjnut.2022.11.009. Epub 2022 Dec 23.
Natural products rich in polyphenols have been shown to lower plasma trimethylamine-n-oxide (TMAO) known for its proatherogenic effects by modulating the intestinal microbiota.
We aimed to determine the impact of Fruitflow, a water-soluble tomato extract, on TMAO, fecal microbiota, and plasma and fecal metabolites.
Overweight and obese adults (n = 22, BMI 28-35 kg/m) were included in a double-blind, placebo-controlled, cross-over study receiving 2×150 mg Fruitflow per day or placebo (maltodextrin) for 4 wk with a 6-week wash-out between interventions. Stool, blood, and urine samples were collected to assess changes in plasma TMAO (primary outcome) as well as fecal microbiota, fecal and plasma metabolites, and urine TMAO (secondary outcomes). In a subgroup (n = 9), postprandial TMAO was evaluated following a choline-rich breakfast (∼450 mg). Statistical methods included paired t-tests or Wilcoxon signed rank tests and permutational multivariate analysis of variance.
Fruitflow, but not placebo, reduced fasting levels of plasma (-1.5 μM, P ≤ 0.05) and urine (-19.1 μM, P ≤ 0.01) TMAO as well as plasma lipopolysaccharides (-5.3 ng/mL, P ≤ 0.05) from baseline to the end of intervention. However, these changes were significant only for urine TMAO levels when comparing between the groups (P ≤ 0.05). Changes in microbial beta, but not alpha, diversity paralleled this with a significant difference in Jaccard distance-based Principal Component (P ≤ 0.05) as well as decreases in Bacteroides, Ruminococccus, and Hungatella and increases in Alistipes when comparing between and within groups (P ≤ 0.05, respectively). There were no between-group differences in SCFAs and bile acids (BAs) in both faces and plasma but several changes within groups such as an increase in fecal cholic acid or plasma pyruvate with Fruitflow (P ≤ 0.05, respectively). An untargeted metabolomic analysis revealed TMAO as the most discriminant plasma metabolite between groups (P ≤ 0.05).
Our results support earlier findings that polyphenol-rich extracts can lower plasma TMAO in overweight and obese adults related to gut microbiota modulation. This trial was registered at clinicaltrials.gov as NCT04160481 (https://clinicaltrials.gov/ct2/show/NCT04160481?term= Fruitflow&draw= 2&rank= 2).
富含多酚的天然产物已被证明可通过调节肠道微生物群降低其具有动脉粥样硬化前效应的血浆三甲胺 N-氧化物(TMAO)。
我们旨在确定水溶性番茄提取物 Fruitflow 对 TMAO、粪便微生物群以及血浆和粪便代谢物的影响。
超重和肥胖成年人(n=22,BMI 28-35kg/m )参与了一项双盲、安慰剂对照、交叉研究,每天接受 2×150mg Fruitflow 或安慰剂(麦芽糊精)治疗 4 周,干预之间有 6 周的洗脱期。收集粪便、血液和尿液样本以评估血浆 TMAO 的变化(主要结局)以及粪便微生物群、粪便和血浆代谢物以及尿液 TMAO(次要结局)。在亚组(n=9)中,在摄入富含胆碱的早餐(约 450mg)后评估餐后 TMAO。统计方法包括配对 t 检验或 Wilcoxon 符号秩检验和置换多元方差分析。
Fruitflow 而非安慰剂可降低空腹血浆(-1.5μM,P≤0.05)和尿液(-19.1μM,P≤0.01)TMAO 以及血浆脂多糖(-5.3ng/mL,P≤0.05)从基线到干预结束。然而,当比较组间时,这些变化仅在尿液 TMAO 水平上具有统计学意义(P≤0.05)。微生物β多样性而非α多样性的变化与基于 Jaccard 距离的主成分的显著差异相平行(P≤0.05),以及组间比较时拟杆菌属、真杆菌属和 Hungatella 的减少和 Alistipes 的增加(P≤0.05,分别)。两组之间在粪便和血浆中的短链脂肪酸(SCFAs)和胆汁酸(BAs)均无差异,但在组内有几个变化,例如粪便胆酸或血浆丙酮酸的增加与 Fruitflow 相关(P≤0.05,分别)。非靶向代谢组学分析表明,TMAO 是组间最具判别力的血浆代谢物(P≤0.05)。
我们的结果支持多酚丰富的提取物可降低超重和肥胖成年人血浆 TMAO 的早期发现,这与肠道微生物群调节有关。该试验在 clinicaltrials.gov 上注册为 NCT04160481(https://clinicaltrials.gov/ct2/show/NCT04160481?term=Fruitflow&draw=2&rank=2)。